2023
Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System
Kinslow C, Rae A, Kumar P, McKhann G, Sisti M, Bruce J, Yu J, Cheng S, Wang T. Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System. Cancers 2023, 15: 876. PMID: 36765837, PMCID: PMC9913704, DOI: 10.3390/cancers15030876.Peer-Reviewed Original ResearchNational Cancer DatabaseCause-specific survivalIntermediate-risk groupCentral nervous systemSolitary fibrous tumor/hemangiopericytomaAssociation of radiotherapyHigh-risk groupOverall survivalRisk categoriesRisk stratificationAssociated with improved survivalPrognostic risk categoriesGross-total resectionKaplan-Meier methodNervous systemCox proportional hazards regressionLow-risk groupProportional hazards regressionEORTC Cooperative GroupRadiotherapy strategiesSEER databaseSurvival benefitProspective trialsCancer DatabaseMeningeal tumors
2017
Use of alternative medicine for cancer and its impact on survival.
Johnson S, Gross C, Park H, Yu J. Use of alternative medicine for cancer and its impact on survival. Journal Of Clinical Oncology 2017, 35: e18175-e18175. DOI: 10.1200/jco.2017.35.15_suppl.e18175.Peer-Reviewed Original ResearchCharlson-Deyo comorbidity scoreConventional cancer treatmentsNational Cancer DatabaseAlternative medicineColorectal cancerCancer treatmentComorbidity scoreCox proportional hazards regressionGreater riskNon-metastatic breastYear of diagnosisAlternative medicine useKaplan-Meier methodSubgroup of patientsAlternative medicine utilizationProportional hazards regressionCancer patient characteristicsDisease-related factorsLog-rank testAnti-cancer treatmentChi-square testPatterns of utilizationHigher socioeconomic statusHormone therapyOverall survival